Smart-Money SignalNeutral · 52/100— Insiders are net sellers over 90 days (-$2.4M, 7 sales vs 4 buys)
Revenue$3.0M
Net Income-$48.4M
EPS$-0.40
Market Cap$4.2B
Price Performance
Historical data including institutional events
Company Profile
M
Michael Davidson
CEO & Executive Director
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.
It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimerâs disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
